.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The VENTURE trial evaluated dupilumab in patients with severe asthma who were dependent on systemic glucocorticoids. Participants received dupilumab or placebo while undergoing a structured reduction in their maintenance oral corticosteroid dose. Dupilumab allowed a significantly greater reduction in daily steroid exposure while also improving asthma control and reducing severe exacerbations in this high-risk population. The study is clinically important because chronic oral corticosteroid exposure carries substantial cumulative toxicity, so a treatment that can reduce steroid dependence has value beyond symptom improvement alone. For HCPs, the key message is to recognize steroid-dependent disease as a marker of severe asthma requiring specialist-level assessment. Before escalating to a biologic, clinicians should confirm adherence, inhaler technique, phenotype, comorbidities, and the accuracy of the asthma diagnosis. Once those foundations are in place, biologic therapy can be used strategically to reduce steroid burden and exacerbation risk. The findings fit the conference’s severe-asthma debate and its emphasis on phenotyping and modern biologic therapy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The VENTURE trial evaluated dupilumab in patients with severe asthma who were dependent on systemic glucocorticoids. Participants received dupilumab or placebo while undergoing a structured reduction in their maintenance oral corticosteroid dose. Dupilumab allowed a significantly greater reduction in daily steroid exposure while also improving asthma control and reducing severe exacerbations in this high-risk population. The study is clinically important because chronic oral corticosteroid exposure carries substantial cumulative toxicity, so a treatment that can reduce steroid dependence has value beyond symptom improvement alone. For HCPs, the key message is to recognize steroid-dependent disease as a marker of severe asthma requiring specialist-level assessment. Before escalating to a biologic, clinicians should confirm adherence, inhaler technique, phenotype, comorbidities, and the accuracy of the asthma diagnosis. Once those foundations are in place, biologic therapy can be used strategically to reduce steroid burden and exacerbation risk. The findings fit the conference’s severe-asthma debate and its emphasis on phenotyping and modern biologic therapy.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
